Authors
Latest:
Dr Kebriaei on the Potential Shift Away From Transplant in ALLPartow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.
Latest:
Dr. Guitera on the RADICAL Trial for MelanomaPascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.
Latest:
Dr Kasi on the Rationale for Analyzing ctDNA to Inform Chemotherapy Decisions in CRCPashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.
Latest:
Park and Kasi Expand on Perioperative Immunotherapy Updates in CRCDrs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.
Latest:
Audience Q&A: Best Practices in Managing HER2-Amplified CRCFielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Latest:
Dr. Whitworth on Treating Breast Cancer With ChemoDr. Pat Whitworth, from the Vanderbilt University Medical Center, Discusses Chemotherapy for Breast Cancer
Latest:
Dr. Whitworth on the Importance of Additional HER2 SubtypingPat Whitworth, MD, medical oncologist at the Nashville Breast Center, discusses the prospective neo-adjuvant NBRST study, which looked at BluePrint functional subtyping versus conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) in breast tumors.
Latest:
Biomarkers Predict Prognosis for Patients With mCRPCA new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer
Latest:
Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast CancerPatricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.
Latest:
Patricia Goldsmith on Financial Stress Associated With Cancer CarePatricia J. Goldsmith, chief executive officer, CancerCare, previews data of a CancerCare study highlighting some of the financial challenges associated with patients who have cancer.
Latest:
Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated LiposarcomaPatricia LoRusso, DO, discusses the importance clinical trial enrollment for patients with MDM2-amplified dedifferentiated liposarcoma.
Latest:
Dr. LoRusso on the Benefit of Genetic Sequencing in SarcomasPatricia LoRusso, DO, discusses the benefit of genetic sequencing in soft tissue sarcomas.
Latest:
Patricia Hofstra on Alternatives to Acquisition in HealthcarePatricia Hofstra, attorney, Duane Morris, discusses options that independent oncology groups have other than being acquired by larger healthcare or oncology systems.
Latest:
Immune Checkpoint Blockade in Cancer: Inhibiting CTLA-4 and PD-1/PD-L1 With Monoclonal AntibodiesInhibitory receptors such as anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) expressed on tumor-specific T cells lead to compromised activation and suppressed effector functions such as proliferation, cytokine secretion, and tumor cell lysis.
Latest:
Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast CancerPatrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.
Latest:
Dr. Brown on the Success of Blinatumomab in the AALL 1331 TrialPatrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.
Latest:
Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy OperationsPatrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.
Latest:
How Does IT Affect Quality of Care?Oncology practices across the country are using computer technology to improve outcomes and quality of care for our patients.
Latest:
Dr. Borgen on the Immuno-Oncology Clinical Trials in Breast CancerPatrick Borgen, MD, discusses the evolution of immuno-oncology clinical trials in breast cancer.
Latest:
Dr. Forde on Updates to the TNM Staging System in Lung CancerPatrick M. Forde, MBBCh, assistant professor of oncology, Johns Hopkins Hospital, discusses updates to the tumor, node, metastasis (TNM) staging system in lung cancer.
Latest:
Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast CancerPatrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.
Latest:
Dr. Ott Discusses Ipilimumab and Nivolumab in MelanomaPatrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses ipilimumab (Yervoy) and nivolumab (Opdivo) both in combination and as a monotherapy for patients with melanoma.
Latest:
Dr. Schoffski Discusses Findings from the CREATE StudyPatrick Schöffski, MD, MPH, head of the Department of General Medical Oncology at the University Hospital Leuven, discusses the findings from the CREATE study during the 2018 AACR Annual Meeting.
Latest:
Dr. Cobb on the Complications of Reimbursement in OncologyDr. Patrick Cobb from the Community Oncology Alliance on the Complications of Reimbursement in Oncology
Latest:
Preventing Clinical Lymphedema With Bioimpedance SpectroscopyEmploying preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.
Latest:
Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLCPaul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.
Latest:
Dr. Bunn on Targeting HER3 in NSCLCPaul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.
Latest:
Dr. Hamlin on the Significance of the ZUMA-I TrialPaul A. Hamlin, MD, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the importance of the ZUMA-I trial results in the field of B-cell lymphoma.
